Sarilumab获批了。因为制造问题晚了半年有点可惜。定价比修美乐便宜30%。
现在就剩下Praluent的outcome数据和官司了 

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi (NYSE:SNY) say the FDA approved their Kevzara (sarilumab) biotech drug for treatment of adults with moderate to severely active rheumatoid arthritis.
Kevzara will carry a list price of $39K/year for the 200 mg and 150 mg doses, which the companies say is ~30% lower than the list price for the two most widely used rival medicines.